On Tuesday, Silexion Therapeutics Corp. ( SLXN ) released new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate.

SIL-204, administered in an extended-release formulation, reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis in human pancreatic tumors harboring a G12D mutation xenografted into mice.

SIL-204 administered subcutaneously inhibited tumor growth in mouse metastatic pancreatic orthotopic models.

A single systemic administration of SIL-204 maintained effective drug levels in rat plasma and tissues for over 56 days.

SIL-204 inhibits key oncogenic KRAS mutations, including G12D,  G12V, G12R, Q61H, and G13D.

Intratumoral administration of SIL-204 microparticles reduced tumor cell numbers by ~3-fold, tumor area by ~1.5-fold, and increased tumor necrosis by ~5-fold after 15 days in human pancreatic cancer xenograft harboring a KRAS G12V mutation in mice.

Also Read: Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

The findings contribute to validating systemic administration as an effective delivery approach, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models.

While the current data shows robust tumor growth inhibition, further studies aim to evaluate its impact on metastases, which the company is cautiously optimistic about.

The company is exploring how this promising data can inform an expanded next-generation treatment strategy for KRAS-driven cancers. It expects to announce details of its expanded development plan shortly.

Price Action: SLXN stock is up 130.2% at $1.33 at last check Tuesday.

Read Next:

Boeing Q4 Earnings: Labor Strikes And Defense Charges Impact Performance, Loses $4.1 Billion In Free Cash Flow